Why Cardiff Oncology Stock Is Crashing Today
Shares of Cardiff Oncology (NASDAQ: CRDF) were trading 19.8% lower as of 11:44 a.m. EST on Friday. The big drop came after the company presented data from a phase 1b/2 study of onvansertib in treating KRAS-mutated metastatic colorectal cancer (mCRC) at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
Biotech stocks don't plunge when investors are happy with clinical trial updates. It's obvious that at least some investors were disappointed by Cardiff's latest news.
Image source: Getty Images.
Source Fool.com
